Shattuck Labs Prices Upsized Public Equity and Warrant Offering
I'm LongbridgeAI, I can summarize articles.Shattuck Labs priced an upsized public equity and warrant offering, selling 10.88 million common shares at $4.00 and pre-funded warrants for 7.87 million shares at $3.9999. Underwriters exercised their full over-allotment option for an additional 2.81 million shares. The transaction, governed by customary terms, aims to provide capital for operations and strengthen the balance sheet as the biopharmaceutical company advances its programs.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Shattuck Labs ( (STTK) ) just unveiled an announcement.
On June 9, 2026, Shattuck Labs, Inc. entered into an underwriting agreement with a syndicate of investment banks for a public offering of 10,879,376 common shares at $4.00 each and pre-funded warrants for 7,870,624 common shares at $3.9999 each. The underwriters exercised in full a 30-day option on June 10, 2026 to purchase an additional 2,812,500 shares, with the offering expected to close on June 11, 2026 under a previously declared effective shelf registration.
The pre-funded warrants are exercisable after issuance, subject to ownership caps that limit any holder’s beneficial stake to between 4.99% and 19.99% of outstanding common stock depending on notice provisions. The transaction, governed by customary underwriting terms and legal opinions, is set to provide Shattuck Labs with additional capital for its operations, potentially strengthening its balance sheet and financial flexibility as it advances its biopharmaceutical programs.
The most recent analyst rating on (STTK) stock is a Buy
with a $18.00 price target.
To see the full list of analyst forecasts on Shattuck Labs stock,
see the STTK Stock Forecast page.
Spark’s Take on STTK Stock
According to Spark, TipRanks’ AI Analyst, STTK is a Neutral.
The score is held down primarily by weak financial performance (large losses and ongoing cash burn on minimal revenue) and bearish technical momentum (negative MACD and price below key moving averages). Recent positive clinical progress and added financing support the outlook but are not enough to offset the core profitability/cash-flow risks.
To see Spark’s full report on STTK stock,
click here.
More about Shattuck Labs
Shattuck Labs, Inc. is a biopharmaceutical company, operating in the U.S., that develops immunotherapy treatments using its proprietary technology platforms. The company focuses on novel oncology therapeutics, targeting cancer patients and related markets where innovative immune-based therapies can improve clinical outcomes and address unmet medical needs.
Average Trading Volume: 672,695
Technical Sentiment Signal: Buy
Current Market Cap: $316.7M
For an in-depth examination of STTK stock, go to TipRanks’ Overview page.